Хлебные крошки
- Главная
-
Аналитика
-
Акции
Акции внутренные
Dynavax Technologies Corporation DVAX
$10.85
На 18:00, 12 мая 2023
Ранг: 2
Ключевые показатели
-
Marketcap
1393921200.00000000
-
week52high
17.48
-
week52low
8.88
-
Revenue
722683000
-
P/E TTM
6
-
Beta
1.47889200
-
EPS
1.93000000
-
Last Dividend
0.00000000
-
Next Earnings Date
02 авг 2023 г. в 10:59
Описание компании
Dynavax Technologies Corporation, a biopharmaceutical company, focuses on developing and commercializing novel vaccines in the United States. The company markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older in the United States and Europe. It also manufactures and sells CpG 1018, the adjuvant used in HEPLISAV-B. Dynavax Technologies Corporation has a collaboration agreement with Valneva Scotland Limited; agreement with Serum Institute of India Pvt. Ltd.; and sublicense agreement with Merck, Sharp & Dohme Corp. The company was formerly known as Double Helix Corporation and changed its name to Dynavax Technologies Corporation in September 1996. Dynavax Technologies Corporation was incorporated in 1996 and is headquartered in Emeryville, California.
Рекомендации
аналитиков
Рекомендации аналитиков
| Grading company | New grade | Previous grade | Recommendation date |
|---|---|---|---|
| HC Wainwright & Co. | Buy | Buy | 29 дек 2021 г. |
| HC Wainwright & Co. | Buy | Buy | 31 авг 2021 г. |
| Goldman Sachs | Buy | 06 авг 2021 г. | |
| HC Wainwright & Co. | Buy | Buy | 05 авг 2021 г. |
| HC Wainwright & Co. | Buy | Buy | 01 февр 2021 г. |
| JMP Securities | Market Outperform | 27 сент 2022 г. | |
| Goldman Sachs | Buy | Buy | 04 ноя 2022 г. |
Свежие комментарии
Свежие комментарии
Оставьте свой голос
Оставьте свой голос
Анонимное голосование
Будет ли рост российского рынка к концу года?
-
Да
87% -
Нет
12%
Проголосовал 8 человек
Покожие компании
Новостная лента
компании
Insider Summary
Insider Summary
| Reporting Name | Acquistion/Disposition | Owned | Transacted | Transaction Date |
|---|---|---|---|---|
| Novack David F | A | 8750 | 8750 | 09 дек 2022 г. |
| Janssen Robert | A | 6250 | 6250 | 09 дек 2022 г. |
| Spencer Ryan | A | 9888 | 9888 | 09 дек 2022 г. |
| Hack Andrew A. F. | D | 3915000 | 1500000 | 06 дек 2022 г. |
| Novack David F | D | 2066 | 52204 | 08 ноя 2022 г. |
| Novack David F | A | 54270 | 1057 | 15 авг 2022 г. |
| Hack Andrew A. F. | D | 5415000 | 3000000 | 15 авг 2022 г. |
| Janssen Robert | D | 6250 | 18750 | 09 авг 2022 г. |
| Janssen Robert | D | 35519 | 7938 | 09 авг 2022 г. |
| Novack David F | D | 8750 | 26250 | 09 авг 2022 г. |
Institutional Ownership
Institutional Ownership
| Holder | Shares | Change | Date Reported |
|---|---|---|---|
| DIMENSIONAL FUND ADVISORS LP | 750976 | 750976 | 30 сент 2022 г. |
| SPDR S&P Biotech ETF | 3415000 | -175718 | 31 авг 2020 г. |
| Vanguard Total Stock Market Index Fund | 2579520 | 0 | 31 авг 2020 г. |
| iShares Russell 2000 ETF | 1910540 | 54720 | 31 авг 2020 г. |
| Vanguard Extended Market Index Fund | 1451850 | -13509 | 31 июл 2020 г. |
| Delaware Healthcare Fund | 760000 | 0 | 31 июл 2020 г. |
| Federated Hermes Kaufmann Fund | 6175000 | 775000 | 30 июн 2020 г. |
| Federated Hermes Kaufmann Small Cap Fund | 4825000 | 605000 | 30 июн 2020 г. |
| UBS (Lux) Equity Fund - Biotech (USD) | 1530950 | 0 | 31 мая 2020 г. |
| Edmond de Rothschild Fund Healthcare | 1390770 | 48 | 31 мая 2020 г. |
Новостная лента
Dynavax Technologies (DVAX) Reports Q1 Loss, Tops Revenue Estimates
Zacks Investment Research
02 мая 2023 г. в 19:09
Dynavax Technologies (DVAX) came out with a quarterly loss of $0.19 per share versus the Zacks Consensus Estimate of a loss of $0.12. This compares to earnings of $0.22 per share a year ago.
The Top 7 Growth Stocks in Biotech
InvestorPlace
03 мар 2023 г. в 18:57
Biotech stocks almost always have the potential for significant growth over time. Companies in the sector operate in areas including drug development, medical devices, and diagnostics.
Dynavax to Present at the Cowen 43rd Annual Health Care Conference
PRNewsWire
01 мар 2023 г. в 16:15
EMERYVILLE, Calif. , March 1, 2023 /PRNewswire/ -- Dynavax Technologies Corporation (Nasdaq: DVAX), a commercial-stage biopharmaceutical company developing and commercializing innovative vaccines, today announced that Kelly MacDonald, Chief Financial Officer, will participate in a fireside chat at the Cowen 43rd Annual Health Care Conference on Wednesday, March 8, at 2:10 p.m.
Dynavax Technologies Corporation (DVAX) Q4 2022 Earnings Call Transcript
Seeking Alpha
23 февр 2023 г. в 19:27
Dynavax Technologies Corporation (NASDAQ:DVAX ) Q4 2022 Results Conference Call February 23, 2023 4:30 PM ET Company Participants Nicole Arndt - Senior Manager, IR Ryan Spencer - CEO Donn Casale - SVP, Commercial Rob Janssen - Chief Medical Officer Kelly MacDonald - CFO Conference Call Participants Phil Nadeau - Cowen & Company Madhu Kumar - Goldman Sachs Matthew Phipps - William Blair Roy Buchanan - JMP Securities Operator Good day, ladies and gentlemen, and welcome to the Dynavax Technologies Fourth Quarter and Full Year 2022 Financial Results. As a reminder, this conference call is being recorded.
The 7 Most Undervalued Long-Term Stocks to Buy in January
InvestorPlace
14 янв 2023 г. в 16:03
With 2022 in the rearview mirror, it's time to hunt for solid, undervalued long-term stocks to buy. First, it's essential to define what is meant by long-term.